{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.0","value":"1.25"},{"groupId":"OG001","spread":"48.7","value":"1.16"},{"groupId":"OG002","spread":"55.3","value":"1.32"},{"groupId":"OG003","spread":"18.2","value":"1.35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"Cmax is the maximum observed plasma concentration at steady state.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG000","title":"Safety Run-In: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG001","title":"Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG002","title":"B: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG003","title":"C: Cobimetinib + Venetoclax + Atezolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK population included participants from Arms B and C who received at least one dose of study medication and for whom at least one evaluable PK sample was collected.","reportingStatus":"POSTED","timeFrame":"Pre-dose (within 1 hr), 2, 4, 6, 8 hrs post-dose on Day 15 of Cycle 1 (cycle length: 28 days)","title":"Cmax of Venetoclax","type":"SECONDARY","unitOfMeasure":"ug/mL"}